West Pharmaceutical Services (WST) Stock
Key stats
- Market cap
- $27.73B
- Price / Earnings ratio
- 49.0x
- EPS (TTM)
- $0.49
- Volume
- Loading
- 52-week high
- $396.00
- 52-week low
- $223.83
- Dividend yield
- 0.22%
- Dividend amount (latest)
- $0.22
- EPS vs analyst estimate
- +16.7%Q3 FY25 · $1.96 vs $1.68
Source: third-party data provider, as of October 24, 2026
EPS estimate: analyst consensus
Compare with WST
Recent news

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
WST

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
WST
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 71.50
- MACD 12/26/9
- 8.05
- EMA 9 of MACD
- 6.26
- MACD histogram
- 1.79
- SMA 50
- $361.15
- Price above SMA 50
- EMA 50
- $364.82
- Price above EMA 50
- SMA 200
- $309.53
- Price above SMA 200
- EMA 200
- $317.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $2.01 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST

West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally?
WST

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
WST

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
WST

West Pharmaceutical (WST) Upgraded to Buy: Here's Why
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
WST

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
WST

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
WST

WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
WST

West Pharmaceutical Services Q2 Earnings Call Highlights
West Pharmaceutical Services Q2 Earnings Call Highlights
WST

WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth
WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth
WST
News tone: automated (AI) classification of the article's content, not a price prediction.
About West Pharmaceutical Services
West Pharmaceutical Services is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of lifesaving and life-enhancing medicines for patients.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michel Lagarde | President, CEO & Director | 1975 |
| Mr. Robert W. McMahon C.M.A. | Senior VP & CFO | 1969 |
| Ms. Annette F. Favorite | Chief HR Officer & Senior VP | 1965 |
| Mr. Shane A. Campbell | SVP & Chief Proprietary Segment Officer | 1980 |
| Mr. Chad R. Winters | VP of Finance & Chief Accounting Officer | 1979 |
| Dr. Devesh Mathur | Senior VP & CTO | — |
| Mr. John P. Sweeney C.F.A. | Vice President of Investor Relations | — |
| Mr. Norman D. Finch Jr. | Senior VP, General Counsel & Corporate Secretary | 1965 |
| Ms. Michele Polinsky | Vice President of Global Communications | — |
| Mr. Rudy J. Poussot | Senior Vice President of Strategy & Corporate Development | 1970 |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 71.50
- MACD 12/26/9
- 8.05
- EMA 9 of MACD
- 6.26
- MACD histogram
- 1.79
- SMA 50
- $361.15
- Price above SMA 50
- EMA 50
- $364.82
- Price above EMA 50
- SMA 200
- $309.53
- Price above SMA 200
- EMA 200
- $317.75
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $400.00
- Average
- $418.67
- High
- $440.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +3.0 | +3.7 | +7.7 | |||||||||
| 2022 | -11.8 | -2.6 | +7.6 | -24.5 | -0.6 | -2.0 | +11.6 | -12.5 | -16.9 | -10.1 | +2.2 | -2.8 |
| 2023 | +13.3 | +16.7 | +8.9 | +4.1 | -8.6 | +12.0 | -2.7 | +9.5 | -8.0 | -14.1 | +9.0 | +0.1 |
| 2024 | +7.0 | -6.1 | +10.3 | -9.7 | -8.8 | +0.2 | -5.7 | +3.7 | -1.3 | +2.7 | +2.9 | +1.5 |
| 2025 | +4.0 | -31.1 | -1.8 | -4.0 | +0.3 | +4.5 | +7.6 | +3.2 | +7.6 | +3.9 | -0.9 | +0.4 |
| 2026 | -16.4 | +7.1 | -0.2 | +17.7 | +7.4 | +13.5 | -6.6 | -2.0 | +9.5 | +8.0 |




